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Abstract
Background: The mechanism(s) responsible for the reduced risk of allergic disease in breastfed infants are not fully 
understood. Using an established murine model of asthma, we demonstrated previously that resistance to allergic 
airway disease transmitted from allergic mothers to breastfed offspring requires maternal B cell-derived factors.
Objective: The aim of this study was to investigate the role of offspring neonatal Fc receptor for IgG uptake by 
intestinal epithelial cells (FcRn) in this breast milk transferred protection from allergy.
Methods: Allergic airway disease was induced during pregnancy in C57BL/6 female mice. These allergic mothers foster 
nursed naive FcRn+/- or FcRn-/- progeny born to FcRn+/- females that were mated to C57BL/6J-FcRn-/- male mice. In 
offspring deficient in FcRn, we expected reduced levels of systemic allergen-specific IgG1, a consequence of decreased 
absorption of maternal IgG from the lumen of the neonatal gastrointestinal tract. Using this model, we were able to 
investigate how breast milk IgG affected offspring responses to allergic sensitization.
Results: Levels of maternal antibodies absorbed from the breast milk of allergic foster mothers were determined in 
weanling FcRn-sufficient or -deficient mice. Maternal transmission of allergen-specific IgG1 to breastfed FcRn-/- offspring 
was at levels 103-104 lower than observed in FcRn+/- or FcRn+/+ mice. Five weeks after weaning, when offspring were 8 
wk old, mice were sensitized and challenged to evaluate their susceptibility to develop allergic airway disease. 
Protection, indicated by reduced parameters of disease (allergen-specific IgE in serum, eosinophilic inflammation in the 
airways and lung) were evident in FcRn-sufficient mice nursed as neonates by allergic mothers. In contrast, FcRn-
deficient mice breastfed by the same mothers acquired limited, if any, protection from development of allergen-
specific IgE and associated pathology.
Conclusions: FcRn expression was a major factor in determining how breastfed offspring of allergic mothers acquired 
levels of systemic allergen-specific IgG1 sufficient to inhibit allergic sensitization in this model.
Background
The beneficial effects of breastfeeding on infant health
have been recognized for thousands of years across
diverse civilizations [1]. As breast milk is the main source
of passive immunity during the early months after birth,
breastfeeding is considered to be the most effective
means of preventing death in young children from infec-
tious causes [2]. In addition, breastfeeding provides nutri-
tional, developmental, psychological, social, economic,
and environmental benefits [3]. While there is over-
whelming evidence supporting the role of breastfeeding
in protecting children from most immune-mediated dis-
eases [4], the components in breast milk responsible for
mediating this protection are not well defined.
Maternal transfer of IgG endows offspring with short-
term protective immunity [5-7]. The human fetus
acquires a substantial amount of maternal IgG in utero,
transported across the placenta by the neonatal Fc recep-
tor (FcRn) [8]. In both humans and rodents, maternal IgG
is acquired from breast milk [9,10], absorbed from the gut
lumen via FcRn-dependent transcytosis in intestinal epi-
thelial cells [11-14]. It is known that mice deficient in
either chain of FcRn (α-chain or β2 microglobulin) have
impaired capacity to absorb maternal IgG from breast
milk and accelerated decay of all IgGs, but not other Ig
isotypes [13,15-19]. The structure of FcRn is well charac-
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terized [12,20] and several studies demonstrate a
dynamic role of this receptor beyond the neonatal period
[21,22].
It remains uncertain how maternal IgG acquired from
breast milk impacts the susceptibility or severity of aller-
gic diseases in children. It is known from animal models
that offspring that receive serum fractions containing
high titers of maternal antigen-specific IgG have sup-
pressed IgE responses and enhanced IgG responses fol-
lowing immunization [23]. Similarly, the presence of
maternal allergen-specific IgG1 at the time of immuniza-
tion can inhibit IgE responses directed against the same
allergen [24,25]. In contrast, passive transfer of allergen-
specific IgG1 followed by local allergen challenge within
the respiratory tract can induce airway eosinophilia
accompanied by hyperresponsiveness to irritants (analo-
gous to induced bronchoconstriction in asthmatics) [26].
The effect of passive immunization on exacerbation of
allergic airway disease (AAD) appears mediated by
enhanced allergen uptake in airway antigen presenting
cells capable of activating proinflammatory CD4+ T cells
[27].
W e  d e m o n s t r a t e d  t h a t  t h e  b r e a s t  m i l k  f r o m  a l l e r g i c
mothers can protect offspring from ovalbumin (OVA)-
induced AAD; with the protective effect dependent on
intact maternal B cell immunity [28]. Offspring nursed by
wildtype allergic foster mothers have less severe OVA-
induced AAD than offspring nursed by B cell deficient
allergic foster mothers. The aim of the current study was
to investigate the role of offspring FcRn in acquiring this
maternal B cell-derived protective factor. We demon-
strated that levels of OVA-specific IgG1 absorbed from
the gut into the circulation of breastfed offspring was
determined by offspring FcRn expression. Furthermore,
the allergen-specific IgG1  absorbed from breast milk
played a major role in preventing allergic sensitization in
this model.
Methods
Animals
C57BL/6J-wildtype or -FcRn-deficient (FcRn-/-) mice
were obtained from Jackson Laboratories (Bar Harbor,
ME) or bred in our colony at the University of CT Health
Center. All mice were fed sterile food and water, and
housed in microisolators under specific pathogen-free
conditions. Their care was in accordance with institu-
tional and Office of Laboratory Animal Welfare guide-
lines.
The generation and characteristics of FcRn-/- mice have
been described [13]. For genotyping, tail pieces were
obtained from mice prior to weaning and again at sacri-
fice. Genomic DNA was isolated using a Wizard
Genomic DNA purification kit (Promega Corporation,
Madison, WI) according to the manufacturer's instruc-
tions. PCR was performed as described [13] using FcRn
o393 Forward 5'-GGATGCCACTGCCCTG-3' and FcRn
o394 Reverse 5'-CGAATTCCCAGTGTATT-3'primers to
amplify a 248 bp fragment from the wildtype allele. Tar-
geting vector specific o395 Forward 5'-GGAATTCCCA-
GTGAAGGGC-3' and FcRn o394 Reverse were used to
amplify a 378 bp fragment from the mutant allele. Gene
segments were amplified using 1 μL of purified DNA in
the presence of Taq DNA Polymerase (Denville Scientific
Inc., Metuchen, NJ), 2.5 mM MgCl2, 10 mM dNTPs, and
0.4 μM o393, o394, o395 primers. After 35 amplification
cycles, DNA fragments were separated by electrophoresis
in a 1.5% agarose gel containing ethidium bromide and
visualized under ultraviolet light. FcRn+/+, FcRn+/-, and
FcRn-/- mice can be distinguished using this strategy [13].
Generation of allergic airway disease (AAD)
Mice were immunized twice, separated by 7 days, by
intraperitoneal injection with 0.32 μg OVA (grade V,
Sigma Chemical Co., St. Louis, MO) adsorbed to 0.08 mg
Al(OH)3 per gram body weight. Ten to 19 days following
the second immunization, animals were exposed daily to
aerosolized antigen generated from 1% OVA in normal
saline with a Bioaerosol Nebulizing Generator (BANG,
CH Technologies, Inc., Westwood, NJ). Exposures were 1
hour for 4 or 7 consecutive days delivered via a nose-only
inhalation exposure chamber with space for exposing 48
mice simultaneously (In-Tox Products, Moriarty, NM).
Allergic mothers were generated using an adaptation of
this protocol essentially as described [29]. Following 7
days of primary aerosol exposure, female mice were
allowed to recover for a period of 50 days and then bred
with naïve C57BL/6J male mice. Pregnant mice were sub-
jected to a secondary challenge with aerosolized OVA
daily, during embryonic days (E) 11-17 of pregnancy
(duration of pregnancy in C57BL/6 mice being 19-20
days).
Sample collection for assessment of OVA-induced AAD
Severity of OVA-induced AAD was evaluated in adult
mice, some of whom had been foster nursed by allergic
versus naïve control mothers. Nomenclature for offspring
was denoted by FcRn genotype followed by nursing
mother's immune status (see T able 1). Mice were sacri-
ficed 24 hours after the last aerosol exposure to deter-
mine serum OVA-specific Ig concentrations, distribution
of airway leukocytes, and to evaluate lung histopathology.
Bronchoalveolar lavage (BAL) was performed under ter-
minal ketamine/xylazine anesthesia. Lungs from each
animal were lavaged in situ with five-1 ml aliquots of ster-
ile saline. Numbers of total leukocytes were obtained
using a Z2™ Coulter Counter® (6-20 μm; Beckman Coulter,
Fullerton, CA). Differential leukocyte counts were enu-Matson et al. Clinical and Molecular Allergy 2010, 8:9
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merated in BAL fluid using fluorescence flow cytometry.
The live leukocyte population was identified by expres-
sion of the leukocyte common antigen CD45 [30]. CD45+
cells were analyzed by forward scatter (FSC) vs. CD11b to
differentiate leukocyte subsets. Using this method,
eosinophils (FSC low/CD11b high) were differentiated
from macrophages (FSC high/CD11b intermediate) and
lymphocytes (FSC low/CD11b negative). If neutrophils
were present, they would be FSC intermediate-high/
CD11b very high (our unpublished results).
For lung histology, the right lower lobe from each ani-
mal was removed, fixed with 10% formalin, processed in a
standard manner, and tissue sections stained with H&E
[30]. The degree of allergic lung inflammation was deter-
mined in specimens without the examiner having knowl-
edge of the experimental condition.
Fluorescence flow cytometry
Monoclonal antibodies used to identify airway leukocytes
were anti-CD45-FITC (30-F11), -CD11b-PerCP-Cy5.5
(M1/70), -CD19-PE (1D3), -CD8α-PerCP (53-6.7), -CD4-
PE (RM4-5), -CD90.2-APC (53-2.1) purchased from BD
PharMingen (San Diego, CA), and -IL33 receptor-biotin
(T1/ST2, [31]) purchased from MD Biosciences (St. Paul,
Minnesota). Cy5-conjugated streptavidin purchased from
Jackson Immuno Research (West Grove, PA) was used to
identify cells labeled with biotinylated antibodies. Cells
(104-106) were incubated with 100 μl of appropriately
diluted antibodies in PBS containing 0.2% BSA and 0.1%
NaN3 for 30 min at 4°C, and then washed with the same
buffer. H-2Kb tetramer containing the OVA-derived pep-
t i d e  S I I N F E K L  w a s  g e n e r o u s l y  p r o v i d e d  b y  D r .  L e o
Lefrançois (University of CT Health Center, Farmington,
CT) and labeling of OVA-specific CD8+  cells was as
described [32]. Relative fluorescence intensities were
determined on a 4-decade log scale by flow cytometric
analysis using a FACSCalibur™ (Becton Dickinson, San
Jose, CA).
Determination of serum IL-5 and OVA-specific Ig levels
In some experiments, serum was collected 24 hours after
the first aerosol challenge for measurement of IL-5 levels
[28]. Serum IL-5 concentrations were determined by
ELISA (Pierce Biotechnology Inc., Rockford, IL). The
assay was performed according to the manufacturer's rec-
ommendation. The minimum concentration of IL-5
detectable with this assay is 1.0 pg/ml.
Serum OVA-specific Ig levels were measured by ELISA
using isotype-specific capture antibodies. BD Falcon
Microtest™ plates (BD Falcon, Franklin Lakes, NJ) were
coated with rat anti-mouse IgG1 (A85-3), IgE (R35-72)
(BD PharMingen) or goat anti-mouse IgA (Southern Bio-
technology Associates), at 2 μg/ml in 0.1 M Carbonate
(pH 9.5) for 16 hours at 4°C. After blocking non-specific
binding, isotype-specific antibodies were captured in
duplicate, as 3-4, two-fold serial dilutions of serum
(within established linear ranges of the standard for each
individual isotype). Detection of antigen-specific anti-
bodies was with OVA-digoxigenin conjugates followed by
anti-digoxigenin-peroxidase (Roche Diagnostics, India-
napolis, IN) [29,33]. Development was with the TMB
microwell peroxidase substrate system (Kirkegaard &
Perry Laboratories, Gaithersburg, MD) and A450 mea-
sured with a Biorad Model 480 microplate reader (Hercu-
les, CA). Limits of detection for OVA-specific IgG1, IgA,
and IgE antibodies in the ELISA were 0.3 ng/ml, 10 ng/
ml, or 5 ng/ml. Limits of detection in serum samples were
determined by the dilution required to achieve positive
readings relative to the lowest reproducible standard con-
centration, thus were 30, 1000, or 50 ng/ml, respectively.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). Differences in antibody levels, airway
inflammatory cells, and cytokine levels between groups
were determined using nonparametric Mann-Whitney or
Kruskal-Wallis tests. All statistical comparisons were per-
Table 1: Identification of offspring based on FcRn genotype and history of exposure to the effects of maternal allergy.
Offspring mice (FcRn genotype/Nursing mother) Prenatal Exposure (Pregnancy) Postnatal Exposure (Nursing)
FcRn+/- /B6naive# B6naive B6naive
FcRn-/- /B6AAD B6naive *B6AAD
FcRn+/- /B6AAD B6naive *B6AAD
FcRn+/+ /B6AAD## B6AAD B6AAD
* Offspring born to naïve females were adoptively nursed by B6AAD mothers.
# Positive control for disease, ## positive control for protection.Matson et al. Clinical and Molecular Allergy 2010, 8:9
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formed with Prism 4 (GraphPad Software, San Diego,
CA). Statistical significance was defined as a p value ≤
0.05. Half life was calculated using the following formula:
t1/2 = (log 0.5/(log Ae/A0)) × t, where t1/2 is the half-life of
antibody decay, Ae is the amount of antibody remaining,
A0 is original amount of antibody at day 0, and t is elapsed
time [34].
Results
FcRn-deficient mice were susceptible to OVA-induced AAD
Prior to performing adoptive nursing studies to elucidate
the role of ingested maternal allergen-specific IgG1 in
protecting offspring from AAD, it was necessary to deter-
mine whether wildtype and FcRn-/- mice developed com-
parable parameters of allergic disease. Five to 6 week old
C57BL/6J wildtype (B6) or FcRn-/-  female mice were
immunized with OVA adsorbed to Al(OH)3 and chal-
lenged with aerosolized OVA as described in the Meth-
ods. Serum collected 24 hours after the first aerosol
challenge demonstrated equivalent levels of IL-5 in
B6AAD and FcRn-/-AAD mice (Figure 1A). Following
sensitization, prior to aerosol challenge, serum IL-5 in
immune competent mice is minimal [28]. Similarly, dur-
ing acute disease following 7 days of OVA aerosol chal-
lenge, comparable levels of OVA-specific IgG1 and IgE
were present in the serum from B6AAD and FcRn-/-AAD
mice (Figure 1B and 1C). Airway leukocyte populations
recovered from the BAL were virtually identical with
equivalent numbers of eosinophils, lymphocytes (Figure
1D and 1E), and macrophages (10-100 × 103 cells per
mouse, data not shown) represented. In addition, similar
numbers of T lymphocytes potentially participating in
disease pathogenesis were recovered from the airways of
B6AAD or FcRn-/-AAD mice. These T cell subsets
included Th2 cells (IL-33R+CD4+) [31] and OVA-specific
CD8+ cells (OVA Tetramer+CD8+) (Figure 1E). Routine
histology of lung sections obtained from B6AAD or FcRn-
/-AAD mice demonstrated patterns of perivascular and
peribronchial inflammation, predominantly composed of
lymphocytes and eosinophils, typical of the pathology we
consistently observe in this model (data not shown)
[28,35]. These data demonstrated that FcRn played little
or no role in development of allergen-specific T and B cell
responses and eosinophilic inflammation of the lungs and
airways when mice were subjected to this acute model of
OVA-induced AAD. Similar airway eosinophilia and his-
tological features between FcRn-sufficient and -deficient
mice using a model of mild AAD were recently reported
by Nakata et al. [36].
Adoptive nursing strategy
To determine the contribution of transferred maternal
allergen-specific IgG1 in the ability of breast milk from
allergic mothers to protect offspring from AAD, we per-
f o r m e d  t h e  e x p e r i m e n t  o u t l i n e d  i n  F i g u r e  2 .  N a i v e
C57BL/6J-FcRn+/-  females (B6naive) were mated to
C57BL/6J-FcRn-/-  males, generating FcRn+/-  or FcRn-/-
progeny. Within 24 hours of delivery, pups with or with-
out FcRn were adoptively nursed by B6AAD foster moth-
ers. Using this strategy where all fostered pups were born
to naïve mothers, acquisition of maternal allergen-spe-
cific Igs was restricted to breast milk. In this experiment,
FcRn-/- offspring were expected to have reduced systemic
levels of OVA-specific IgG1  as a consequence of
decreased absorption of maternal IgG from the lumen of
the neonatal gastrointestinal tract [13]. Five weeks follow-
ing weaning, all offspring were subjected to allergic sensi-
tization and aerosol challenge to induce AAD as
described in the Methods. Requisite controls to evaluate
how acquiring allergen-specific IgG1  in breast milk
affected severity of AAD were FcRn+/- pups that were
born to and remained with their naïve FcRn+/- mothers
(positive controls for disease) and wildtype FcRn+/+ pups
that were born and remained with their B6AAD mothers
(positive controls for protection) [28].
Levels of OVA-specific IgG1 absorbed from breast milk of 
allergic mothers
FcRn+/- or FcRn-/- offspring were nursed by B6AAD foster
mothers using the adoptive nursing strategy (Figure 2),
FcRn+/+ offspring were nursed by their own B6AAD birth
mothers. Sera were obtained from FcRn+/+, FcRn+/-, or
FcRn-/- offspring immediately prior and 4 weeks after
weaning (at 24 and 52 days of life) for measurement of
passively acquired maternal antibodies. As anticipated, at
24 days of life FcRn+/+ and FcRn+/- offspring had similar
OVA-specific IgG1 serum concentrations (14,280 ± 1861
μg/ml and 6,954 ± 1259 μg/ml respectively; Figure 3). In
contrast, FcRn-/- offspring displayed significantly reduced
OVA-specific IgG1  serum concentrations (< 6 μg/ml).
Thus, at weaning OVA-specific IgG1 antibodies were evi-
dent in the serum of FcRn-/- offspring nursed by B6AAD
mothers, however the magnitude was 103-104 lower than
that observed in FcRn+/+ and FcRn+/- offspring. No OVA-
specific antibodies were detected in the serum of pups
nursed by B6naive mothers (data not shown).
At 52 days of life (4 weeks after weaning and 1 week
prior to the 1st OVA immunization), OVA-specific IgG1
concentrations were approximately 10 fold lower in
FcRn+/- and FcRn+/+ offspring than detected at 24 days of
life (weaning). At this time, OVA-specific IgG1 antibodies
were no longer detected in the serum of FcRn-/- offspring
(limit of detectection was 30 ng/ml based on serum dilu-
tion of 1:100). There was no difference in the t1/2 of
ingested maternal IgG1 in serum of FcRn+/+ or FcRn+/- off-Matson et al. Clinical and Molecular Allergy 2010, 8:9
http://www.clinicalmolecularallergy.com/content/8/1/9
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Figure 1 Similar parameters of OVA-induced AAD in wildtype or FcRn deficient mice. Five to 6 week old female C57BL/6J wildtype (B6AAD) or 
FcRn deficient (FcRn-/- AAD) mice were given two immunizations with OVA-Al(OH)3 followed by challenge for 7 days with 1% aerosolized OVA (daily 
exposure time 60 min). Parameters of disease severity measured were (A) serum IL-5 concentrations determined 24 hours after the first aerosol expo-
sure; (B and C) serum OVA-specific Ig titers determined 24 hours after the last aerosol exposure; and (D) distribution of airway leukocytes determined 
by fluorescence flow cytometry as described in the Methods. Numbers of IL-33R+ or OVA-tetramer+ cells were of CD4+ and CD8+ T lymphocytes, re-
spectively. Results expressed as means ± SEM and represent 5-6 mice per group. There were no statistical differences in disease parameters between 
groups. Similar parameters of disease were obtained in an independent experiment.
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Figure 2 Strategy to determine the role of "offspring" FcRn in the maternal transmission of allergic protection.
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spring (~8.5 days) when calculated from OVA-specific
IgG1 levels in individual mice at 24 days (weaning) and 52
days of life. The t1/2 values were similar to those previ-
ously reported (9 days) when adult FcRn+/- mice were
injected intraperitoneally with tracer anti-TNP IgG1 [13].
Given the inability to detect OVA-specific IgG1 antibod-
ies at 52 days of life in FcRn-/- offspring, we were unable to
calculate the t1/2 of maternal IgG1 in these mice. Previous
studies have established that IgG decay is accelerated in
mice lacking FcRn [13,15,16]. Using the reported t1/2 of
1.4 days for IgG decay in serum of FcRn-/- mice [13], the
amount of maternal OVA-specific IgG1 in FcRn-/- off-
spring at 52 days of life was calculated to be 1.9 × 10-3 ng/
ml, which is well below the limit of detection (30 ng/ml)
in the ELISA assay. At 52 days of life, OVA-specific IgA or
IgE antibodies were not detected in the serum of FcRn+/+,
FcRn+/-, or FcRn-/- offspring nursed by B6AAD mothers
(unpublished results; limits of detection: 1000 ng/ml and
50 ng/ml respectively based on serum dilutions). How-
ever, using the levels of maternal OVA-specific IgA pres-
ent in offspring serum at weaning and the reported t1/2 of
injected IgA of 1.4 days [13], the maximum level of
maternal OVA-specific IgA present at the time of the first
immunization would be < 0.2 pg/ml.
Maternal allergen-specific IgG1 prevented allergic 
sensitization
Adult (59 day old) mice (identified as described in Table
1) nursed until 24 days of age by naïve or allergic mothers
were subjected to OVA-induced AAD as described in the
Methods. As expected, after immunization and 4 day
aerosol challenge, a robust AAD response was observed
in FcRn+/- offspring nursed by B6naive mothers (FcRn+/-/
B6naive, positive controls for disease). This was demon-
strated by elevated serum OVA-specific IgE levels (1,187
ng/ml ± 435 ng/ml; Figure 4A) airway eosinophils (1,786
± 406 × 103; Figure 4B), mononuclear cells (381 ± 54 ×
103, data not shown), and lymphocyte subsets (Figure
4C). In contrast, FcRn-sufficient offspring nursed by
B6AAD mothers (FcRn+/+/B6AAD [positive controls for
protection] and FcRn+/-/B6AAD) demonstrated attenu-
a t e d  p a r a m e t e r s  o f  d i s e a s e  a s  c o m p a r e d  t o  t h o s e
observed in the positive control FcRn+/-/B6naive mice.
Most notable and reproducible between experiments was
the greater than 10-fold lower levels of OVA-specific IgE
observed in the serum of FcRn+/+/B6AAD (<50 ng/ml;
Figure 4A) and FcRn+/-/B6AAD (120 ng/ml ± 48 ng/ml;
Figure 4A) offspring. Ten-fold lower levels of OVA-spe-
cific IgG1 were also observed in serum from the same
groups of mice (data not shown). Similarly, a 4-fold
reduction in numbers of eosinophils (Figure 4B), 2- to 3-
fold reduction in numbers of mononuclear cells (data not
shown), and decreased numbers of lymphocyte subsets
(Figure 4C) were recovered from the airways of FcRn+/+/
B6AAD and FcRn+/-/B6AAD offspring as compared to
the FcRn+/-/B6naive positive controls. This included a 3-
fold reduction in the number of airway Th2 cells (IL33R+
CD4+) (Figure 4C).
Interestingly, FcRn-deficient offspring nursed by
B6AAD mothers (FcRn-/-/B6AAD) were not as protected
from developing OVA-induced AAD as FcRn-sufficient
offspring that were nursed by the same B6AAD mothers.
Similar concentrations of OVA-specific IgE were
observed in the serum of FcRn-/-/B6AAD offspring (924
ng/ml ± 214 ng/ml) as compared to FcRn+/-/B6naïve con-
trols. Analysis of BAL leukocytes also demonstrated simi-
lar numbers of airway eosinophils (958 ± 233 × 103;
Figure 3 Absorption of OVA-specific IgG1 by breastfed offspring 
was determined by offspring FcRn expression. Naive C57BL/6J-
FcRn+/- females (B6naive) were mated to C57BL/6J-FcRn-/- males. Prog-
eny of this mating were FcRn+/- or FcRn-/-. C57BL/6J OVA-induced AAD 
(B6AAD) foster mothers were generated (as described in the Methods) 
and within 24 hours of delivery, pups with or without FcRn were adop-
tively nursed by B6AAD foster mothers. Serum was collected from 
FcRn+/+, FcRn+/-, or FcRn-/- offspring at weaning (24 days of life) and 52 
days of life (1 week prior to OVA-immunization) and concentrations of 
OVA-specific Igs were measured by ELISA. OVA-specific Igs were ab-
sent from the serum of pups nursed by B6naive mothers (data not 
shown). Results are presented as 12-19 individual mice per group and 
the red line is the mean. There were no significant differences in serum 
concentrations of OVA-specific IgG1 antibodies between FcRn+/+ and 
FcRn+/- offspring at 24 days or 52 days of life. At 24 days of life, serum 
OVA-specific IgG1 concentrations were significantly lower in FcRn-/- off-
spring when compared to FcRn+/+ or FcRn+/- offspring (p ≤ 0.01). At 52 
days of life, OVA-specific IgG1 antibodies were no longer detected in 
the serum of FcRn-/- offspring (limit of detection 30 ng/ml).
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Figure 4B), mononuclear cells (266 ± 41 × 103, data not
shown), and lymphocyte subsets (Figure 4C). Further-
more, histopathologic examination of lung tissue
obtained from FcRn-/-/B6AAD offspring demonstrated
extensive perivascular and peribronchiolar cuffing, and
eosinophilic inflammation, similar to that previously
reported for wildtype C57BL/6 mice in this model (Figure
4D) [35]. In contrast, there was notably less allergic
inflammation in lung tissue obtained from FcRn+/+/
B6AAD and FcRn+/-/B6AAD offspring (Figure 4D). Thus,
consistent with our previous study [28], FcRn-sufficient
offspring nursed by wildtype OVA-immune mothers
were protected from developing severe OVA-induced
AAD. In contrast, limited, if any, protection from devel-
opment of OVA-induced AAD was transmitted from
allergic mothers to FcRn-deficient offspring.
Discussion
There is overwhelming evidence supporting the role of
breastfeeding in protecting children from most immune-
mediated diseases [4]. Despite this, it is not clear whether
this applies to prevention of allergic disease in situations
when mothers are allergic. Possible explanations for the
inconsistent effects of breastfeeding on allergy and
asthma prevention may be the immunologic complexities
of breast milk itself and potential changes in composition
in the context of maternal allergy or allergen exposure.
Breast milk contains a multitude of biologically active
components and some elements are thought to protect
the infant from developing allergies, whereas others
might promote allergic sensitization [37].
W e recently demonstrated that transmission of resis-
tance to AAD from allergic mothers to nursing offspring
is dependent on B cell-derived factors in breast milk [28].
By comparing offspring of mothers with OVA- versus
BSA-induced lung disease, we also established that the
maternally transferred protection from AAD is antigen-
specific [29]. Based on these findings, we hypothesized
that antigen-specific Igs in breast milk were major con-
tributors to this protective effect. We previously demon-
strated that allergen-specific IgG1, IgA and IgE are
absorbed from the neonatal gastrointestinal tract into the
systemic circulation of naïve mice nursed by allergic
mothers [28,29]. No allergen-specific IgG2a is elicited fol-
lowing immunization with OVA adsorbed to Al(OH)3 or
after the aerosol challenge in our model of AAD, thus is
not absorbed by offspring nursed by allergic mothers
[29]. In the present study, although maternal allergen-
specific IgG1, IgA and IgE were present at weaning in
naïve FcRn-sufficient mice foster nursed by allergic
mothers, it appeared that allergen-specific IgG1 was the
Figure 4 FcRn expression was required for offspring to obtain the protective factor(s) from breast milk. Pups are those identified in Table 1. 
Following weaning, allergic airway disease was elicited in 8 week old offspring by two immunizations with OVA-Al(OH)3 followed by challenge for 4 
days with 1% aerosolized OVA (daily exposure time 60 min). Parameters of disease severity measured were (A) OVA-specific IgE titers determined by 
ELISA; and (B and C) distribution of leukocyte populations in the airways determined by fluorescence flow cytometry. (D) Representative lung sections 
after OVA-aerosol challenge. Results expressed as means ± SEM and represent 12-19 mice per group. * p ≤ 0.05, ** p ≤ 0.01, or *** p ≤ 0.001 when 
compared to FcRn+/-/B6naive offspring (positive controls for disease) similarly subjected to AAD. Similar differences in OVA-specific IgE titers and his-
topathology between groups were obtained in an independent experiment.
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only isotype whose levels were sustained until allergic
sensitization. This was not the case in FcRn-deficient
mice where the low levels of maternal allergen-specific
IgG1 present at weaning were undetectable at the time of
immunization. In mice, as in humans, the transfer of
breast milk IgG across the intestinal epithelium is medi-
ated by FcRn [9]. Based on these and other data presented
in this report, we were able to show that expression of
FcRn was important for offspring to acquire sufficient
levels of allergen-specific IgG1 from the breast milk of
allergic mothers to prevent allergen-specific IgE
responses. A distinct experimental strategy to address
this research question was recently reported by Nakata et
al. [36]. Importantly, the data derived from their studies
led them to the same overall conclusion, that maternal
IgG affects development of allergy in offspring. Thus, the
two studies synergize to advance the understanding of the
biology of FcRn as it applies to uptake of maternal IgG
from the lumen of the gastrointestinal tract, and of how
absorbed maternal allergen-specific IgG and offspring
FcRn contribute to enhancing protection from allergic
sensitization and disease.
To determine the role of FcRn in the postnatal acquisi-
tion of allergic protection, it was necessary to establish
that FcRn-deficient mice were competent to develop
OVA-induced AAD. After OVA-immunization and aero-
sol challenge, FcRn-/- AAD mice demonstrated equivalent
parameters of acute disease as wildtype B6AAD mice
(this report and [36]). Of particular interest were similar
titers of OVA-specific IgG1 antibodies in FcRn-/- AAD
and B6AAD mice in serum collected 24 hours after the
last aerosol exposure. Thus, despite the accelerated decay
of IgG in FcRn-deficient mice [13,15,16], the initial anti-
body titers following aerosol challenge were unaffected.
These results suggest that lymphocyte responses to aller-
gic sensitization and challenge, including the generation
of OVA-specific memory CD4+ T cells and B cells, were
intact in FcRn-deficient mice. Furthermore, differentia-
tion of memory B cells to antibody-producing plasma
cells appeared unaffected by the absence of FcRn.
FcRn-/- offspring had impaired capacity to absorb OVA-
specific IgG1 from the breast milk of allergic mothers. At
24 days of life, 103 - 104 lower levels of antigen-specific
IgG1 were detected in the serum of FcRn -/- offspring as
compared to FcRn+/+ or FcRn+/- offspring nursed under
the same conditions. This is consistent with what is
known regarding the significant role of FcRn in mediating
absorption of breast milk IgG [13,17]. However, in the
previous study, while the TNP-specific IgG1 injected into
pregnant mice was present in the serum of breastfed
FcRn+/- neonates (10-20 μg/ml), it was not detected (<80
ng/ml) in their littermate FcRn-/- mice [13]. Thus, the
existence or impact of an FcRn-independent component
of maternal IgG uptake has not been appreciated. It is
possible the low levels of antigen-specific IgG1 detected
in the serum of FcRn-/- offspring are acquired via passive
diffusion across the intestinal epithelium, although it
remains to be determined whether this is the case. It is
known that this mucosal barrier is more permeable in
neonates with gut "closure" (cessation of Ig absorption)
occurring at weaning [10].
Although we demonstrated that FcRn-independent
uptake of maternal IgG can occur in neonatal mice, we
found that >99.9% of IgG absorbed in wildtype mice was
via an FcRn-dependent mechanism (see Figure 3). In
addition to mediating transcytosis of IgG across the
intestinal epithelium [11-13], FcRn modulates IgG
homeostasis [13,15,16]. Thus, we were able to perform
the first study that quantified the rate of decay of
absorbed maternal IgG1 acquired exclusively from breast
milk (~8.5 days). As compared to IgG acquired via intra-
venous injection, it is possible that ingested IgG selected
by FcRn for absorption from the gut lumen has a higher
binding affinity for FcRn systemically, and thereby has
increased protection from catabolism. It is not clear
whether or not this is the case since a direct comparison
of half-lives of the same population of IgG1 molecules fol-
lowing ingestion or injection of mice at the same age has
not been made. Furthermore, there appears to be a lack of
consensus in the field regarding the t1/2 of injected IgG
[13,15,16,18,19]. The explanation for the diversity in
results from different laboratories is not obvious, but
could be due to different routes of injection - intraperito-
neal versus intravenous, or structural features of the
injected monoclonal antibodies tested that contribute to
their inherent strengths of interaction with FcRn.
Other studies demonstrate that under the appropriate
experimental conditions, breast milk may be protective
against [28,36,38-41] or increase susceptibility to [42] the
development of allergic disease in offspring. It is impor-
tant to understand the mechanistic basis for differences
in the effect of breast milk during this early period of
immune maturation. In our studies, it is possible that
maternal antigen-specific IgG1  absorbed into the sys-
temic circulation of offspring, neutralized the antigen -
clearing it from the circulation prior to its recognition by
cells of the adaptive immune system. This is supported by
data from offspring nursed by allergic mothers where few,
if any, FcRn-sufficient offspring produced allergen-spe-
cific IgE at 7 days after the second intraperitoneal immu-
nization (data not shown). Neutralization of pathogens is
known to occur when infants receive certain live vaccines
(e.g. measles virus) in the presence of preexisting mater-
nal antibodies. This is a major factor for delaying infant
immunization until the majority of maternal antibodies
have disappeared [43,44]. The functions of maternal anti-Matson et al. Clinical and Molecular Allergy 2010, 8:9
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bodies in determining immune parameters in offspring
can be influenced by the presence or absence of antigen
and the ratio between them [45]. Interestingly, in some
experiments performed in this and our other related
studies evaluating how allergic mothers influence param-
eters of allergic disease in offspring, allergen-specific
IgG1 and IgE responses were virtually absent without pro-
found effects on airway eosinophilia. Since airway
eosinophilia can occur in the complete absence of B cells
[28], this implies that protection from AAD acquired
from allergic mothers in our model has more robust
downstream effects on B cell than T cell parameters of
disease. Thus, in addition to allergen neutralization, it is
likely that maternal antigen-specific IgG1/allergen
immune complexes contribute to determining the out-
come of offspring responses to allergic sensitization [46].
It should be noted that not all maternal Igs have benefi-
cial effects in progeny. Recently, a murine model of pea-
nut allergy demonstrated that maternal derived anti-
peanut IgG1 is associated with anaphylactic reactions in
offspring [47]. In addition, several autoimmune diseases
such as systemic lupus erythematosus are known to result
in transmission of maternal IgG's that have deleterious
effects in progeny [48]. The ability of maternal IgG to
mediate differential effects in offspring may be related to
affinities for individual FcγRs resulting from Fc glycosyla-
tion. IgG is known to contain a single N-linked gycan at
Asn297 of the Fc domain, and variations of this covalently
linked complex carbohydrate determines binding interac-
tions with individual FcγRs [49,50]. Fc sialyation of IgG1
results in a reduced binding affinity for the activating
receptor FcγRIII and promotes anti-inflammatory effects
through the inhibitory receptor FcγRIIB [49]. It is known
that several autoimmune diseases are associated with
individual glycoforms of IgG [51,52]. Perhaps the struc-
ture of glycans on antigen-specific IgGs varies during the
pathogenesis of allergic disease, or is influenced by the
environment at the site of the allergen challenge (such as
the lung or gut mucosa). Control of post-translational
modification of carbohydrate residues on IgGs could be
determined during plasma cell differentiation from mem-
ory B cells, and/or modified by glycosylation or de-glyco-
sylation enzymes unique to specific tissue environments
or disease states. It is possible that physiological changes
during lactation itself play a role in the characteristics of
maternal IgG acquired by offspring to influence whether
maternal IgG transfers increased risk or protection from
a l l e r g i c  d i s e a s e .  R e c e n t  r e s u l t s  f r o m  V i c t o r  e t  a l .  [ 4 1 ]
could be supportive of this idea. In their study, neonates
nursed by immunized mothers exhibit marked inhibition
of B and T cell responses following immunization. In
contrast, postnatal injected anti-allergen IgG (purified
from serum of immunized mice) failed to modulate
expression of F cγRIIB or regulate B or T cell cytokine
production.
Our findings suggest a serum concentration limit of
absorbed maternal antigen-specific IgG sufficient to pro-
tect offspring from AAD. This concept is supported by
data from FcRn+/+ or FcRn+/- offspring, where serum lev-
els of antigen-specific IgG1 of 105 - 106 ng/ml at 52 days of
life appeared sufficient to protect offspring from AAD
initiated one week later. Significantly reduced levels of
antigen-specific IgG1 i n  t h e  s e r u m  o f  w e a n l i n g  F c R n -/-
mice, that decayed to negligible levels prior to immuniza-
tion, resulted in the absence of protection from AAD.
Interestingly, the concentration limit of maternal IgG
needed to protect offspring from AAD appears to be
dependent on the severity of disease elicited in murine
models, with lower levels of absorbed allergen-specific
IgG1 (60-90 ng/ml) being sufficient to protect from mild
disease [36]. Additional experimentation aimed at defin-
ing the contributions of serum concentrations of mater-
nal IgG, immune complexes and structural glycoforms
sufficient to protect offspring from allergic sensitization
will be important.
Conclusion
Our study demonstrates that breast milk factors obtained
via FcRn (e.g. IgG) result in reduced severity of allergic
airway disease in offspring. Based on these results one
could consider increasing maternal antigen-specific IgG
levels (e.g. maternal immunization) as a possible method
for the prevention of allergic disease in progeny. Further
clarification of the IgG levels required to protect off-
spring, the structural properties of antibodies involved,
and their interaction with receptors at various locations
(e.g. spleen, intestine, and thymus) in the neonate are
important in understanding how passive immunity influ-
ences the development of allergy in offspring
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